Axogen (LTS:0HKD) Research & Development: $34.3 Mil (TTM As of Mar. 2026)


LTS:0HKD Axogen Inc LTS:0HKD
62 GF Score
Price $44.67
GF Value $15.43
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Axogen Research & Development?

Axogen LTS:0HKD -0.38% 62 Research & Development is $34.3 Mil as of Mar. 2026. GuruFocus rates LTS:0HKD with a GF Score™ of 62/100 and a GF Value™ of $15.43 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Axogen's Research & Development for the three months ended in Mar. 2026 was $7.5 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $34.3 Mil.

Axogen  (LTS:0HKD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Axogen Research & Development Related Terms

Axogen Research & Development Historical Data

* Premium members only.

The historical data trend for Axogen's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axogen Research & Development Chart

Axogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.18 25.63 27.34 27.77 32.89

Axogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.09 6.85 7.57 12.38 7.52
LTS:0HKD
62GF Score
Axogen Inc LTS:0HKD
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axogen Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $34.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $34.3 Mil mean?
Axogen (LTS:0HKD) has a Research & Development of $34.3 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Axogen and its competitors.
Is Axogen's Research & Development too high?
Axogen's current Research & Development is $34.3 Mil. Overall, Axogen has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Axogen's Research & Development compare to TMDX and BFLY?
Axogen's Research & Development of $34.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Axogen and its competitors. Axogen's current Research & Development is $34.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axogen stock overvalued right now?
Based on GuruFocus' analysis, Axogen (LTS:0HKD) is currently considered Significantly Overvalued. The stock's GF Value™ is $15.43, compared to a current price of $44.67 — trading 189.5% above its estimated fair value. The current Research & Development is $34.3 Mil. Axogen's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Axogen (LTS:0HKD), the current Research & Development is $34.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axogen (LTS:0HKD) Overvalued in 2026?

Based on GuruFocus' analysis, Axogen stock appears to be overvalued. The current stock price of $44.67 is trading 189.5% above its estimated GF Value™ of $15.43. GuruFocus considers Axogen to be Significantly Overvalued.

Key valuation signals for LTS:0HKD:

  • Research & Development: $34.3 Mil
  • GF Value™: $15.43 vs. price of $44.67 (189.5% above fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the LTS:0HKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axogen Business Description

Other Exchanges AXGN:USALT3:Germany
Address 13631 Progress Boulevard, Suite 400, Alachua, FL, USA, 32615
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
62GF Score

Get the complete analysis for LTS:0HKD

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.67
Price
$15.43
GF Value